Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03316560 · ClinicalTrials.gov registry record · Phase 1

Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations

A Phase 1 study of X-Linked Retinitis Pigmentosa, sponsored by Beacon Therapeutics.

Active
Registry status
Phase 1
Development phase
29
Enrollment target
4
Study locations

NCT03316560 is a Phase 1 study of X-Linked Retinitis Pigmentosa that is active but no longer recruiting, run by Beacon Therapeutics. The registered enrollment target is 29 participants, below the 55-participant average among 8 other X-Linked Retinitis Pigmentosa trials with a reported enrollment target (47% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03316560, a Phase 1 study of X-Linked Retinitis Pigmentosa, is active but no longer recruiting, sponsored by Beacon Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
29 participants
Enrollment target
4
Study locations

Study Summary

This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retinitis pigmentosa caused by RPGR mutations.

Conditions Studied

X-Linked Retinitis Pigmentosa

Interventions

  • BIOLOGICAL rAAV2tYF-GRK1-RPGR

Study Locations (4)

North Carolina

  • Duke University - Durham

Ohio

  • Cincinnati Eye Institute - Cincinnati

Oregon

  • Casey Eye Institute - Portland

Texas

  • Retina Foundation of the Southwest - Dallas

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2018-04-16
Est. Completion 2025-03
Phase Phase 1

Sponsor

Beacon Therapeutics

12 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03316560

The ClinicalTrials.gov registry entry for NCT03316560 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55-participant average among 8 other X-Linked Retinitis Pigmentosa trials with a reported enrollment target (47% lower). The listed sponsor is Beacon Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with X-Linked Retinitis Pigmentosa appearing as the primary indexed condition, and to 1 intervention - of which rAAV2tYF-GRK1-RPGR is the first listed.

NCT03316560 reports 4 study locations spanning 4 distinct geographic areas - top geographies include North Carolina, Ohio, Oregon.

Frequently Asked Questions

What is clinical trial NCT03316560 about?

NCT03316560 is a clinical study titled "Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations". This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retinitis pigmentosa caused by RPGR mutations.

What is the current status of trial NCT03316560?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2018-04-16. Estimated completion is 2025-03.

What conditions does trial NCT03316560 study?

This clinical trial studies the following conditions: X-Linked Retinitis Pigmentosa.

What interventions are being tested in trial NCT03316560?

The interventions under investigation include: rAAV2tYF-GRK1-RPGR (BIOLOGICAL).

Who is sponsoring clinical trial NCT03316560?

This trial is sponsored by Beacon Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03316560 being conducted?

This trial has 4 study locations across North Carolina, Ohio, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for X-Linked Retinitis Pigmentosa

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

X-Linked Retinitis Pigmentosa

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.